# A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer(PANKU-Breast02)

> **NCT06382142** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Sichuan Baili Pharmaceutical Co., Ltd.** · enrollment: 418 (actual)

## Conditions studied

- Triple-Negative Breast Cancer

## Interventions

- **DRUG:** BL-B01D1
- **DRUG:** Eribulin
- **DRUG:** Vinorelbine
- **DRUG:** Gemcitabine
- **DRUG:** Capecitabine

## Key facts

- **NCT ID:** NCT06382142
- **Lead sponsor:** Sichuan Baili Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-06-21
- **Primary completion:** 2026-06
- **Final completion:** 2026-06
- **Target enrollment:** 418 (ACTUAL)
- **Last updated:** 2026-04-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06382142

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06382142, "A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer(PANKU-Breast02)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06382142. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*